Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946792 | 0.95 | HTR2C (0.48) | FFAR1PTPN1HTR2CHTR2BGRM5 | |
| SCHEMBL2950490 | 0.90 | FFAR1 (0.49) | FFAR1PTPN1GRM5PTGDR2PTGES | |
| SCHEMBL3936713 | 0.84 | GRM5 (0.45) | FFAR1PTPN1GRM5KCNH2PTGES | |
| SCHEMBL31345011 | 0.83 | SHMT1 (0.42) | HTR2CHTR2BEGFRCHRNB4CHRNA3 | |
| SCHEMBL1591331 | 0.83 | FFAR1 (0.51) | FFAR1PTPN1GRM5PTGDR2PTGES | |
| SCHEMBL2180350 | 0.83 | HTR2C (0.51) | HTR2CHTR2BGRM5EGFRCHRNB4 | |
| SCHEMBL7517707 | 0.82 | FFAR1 (0.62) | FFAR1PTPN1PTGDR2CTSKPTGES | |
| SCHEMBL3937119 | 0.81 | GRM5 (0.47) | FFAR1PTPN1HTR2CHTR2BGRM5 | |
| SCHEMBL2236377 | 0.81 | FFAR1 (0.53) | FFAR1PTPN1GRM5PTGES | |
| SCHEMBL2946865 | 0.80 | GABRP (0.47) | FFAR1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1781608-B1 | INDOLE DERIVATIVES COMPRISING AN ACETYLENE GROUP AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7405236-B2 | Indole derivatives comprising an acetylene group | HOFFMAN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-7253192-B2 | Phenyl derivatives comprising an acetylene group | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060035956-A1 | e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis | HOFFMANN-LA ROCHE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20060004091-A1 | Phenyl derivatives comprising an acetylene group | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035956-A1 | e.g. {6-[5-(4-trifluoromethoxy-phenyl)-pent-4-ynyloxy]-indol-1-yl}-acetic acid; peroxisome proliferator activated receptor PPAR delta or PPAR alpha agonist; antidiabetic, antiinflammatory agent, cardiovascular disorders; non-insulin dependent diabetes, insulin resistance, atherosclerosis | PPARD, PPARG, PPARA | FFAR1 5/4885PTPN1 269/4885HTR2C 2112/4885 |
| US-20060004091-A1 | Phenyl derivatives comprising an acetylene group | PPARD, PPARA, PPARG | FFAR1 40/4885PTPN1 2553/4885HTR2C 1268/4885 |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | S1PR1, S1PR2, S1PR5 | FFAR1 22/4885PTPN1 525/4885HTR2C 1844/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | FFAR1 193/4885PTPN1 680/4885HTR2C 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.